Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.30 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.30 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12231026 | 1.00 | L3MBTL1 (0.30) | L3MBTL1SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL9823374 | 0.78 | SLC6A1 (0.33) | L3MBTL1SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL9823369 | 0.78 | SLC6A1 (0.33) | L3MBTL1SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL8133320 | 0.78 | SLC6A1 (0.33) | L3MBTL1SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL7755842 | 0.76 | GPBAR1 (0.34) | L3MBTL1SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL4612981 | 0.75 | SLC6A1 (0.31) | SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL8755099 | 0.75 | SLC6A1 (0.31) | SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL7757782 | 0.75 | L3MBTL1 (0.36) | L3MBTL1 | |
| SCHEMBL9118328 | 0.73 | SHBG (0.38) | — | |
| SCHEMBL9118331 | 0.73 | SHBG (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557828-B2 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBVIE INC. (US) | 2013-10-15 | — | — | US | disclosed |
| EP-2142552-B1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBOTT LAB (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20120041003-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | disclosed |
| US-8076344-B2 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBOTT LABORATORIES (US) | 2011-12-13 | — | — | US | disclosed |
| US-20080293713-A1 | Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme | ABBOTT LABORATORIES (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041003-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | DGAT1, DGAT2, LCAT | L3MBTL1 843/4885SLC6A1 2852/4885SLC6A12 4161/4885 |
| US-20080293713-A1 | Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme | DGAT1, DGAT2, LCAT | L3MBTL1 843/4885SLC6A1 2852/4885SLC6A12 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.